Israeli researchers from Hebrew University and the Military Medicine Institute, in collaboration with the university's medical faculty, the Hadassah Medical Organization (HMO) and the IDF Medical Corps, have discovered a promising new treatment for hemorrhagic shock, a potentially fatal condition caused by severe blood loss, according to The Jerusalem Post.
The study, published in the journal Scientific Reports, shows that activating protein kinase C-epsilon (PKC-ε) significantly improves initial survival rates and hemodynamic stability after a severe hemorrhage. Dr. Liza Douiev from the HMO Department of Genetics and Dr. Hanna Rosenman from the Hadassah Department of Neurology were among the HMO staff who contributed to the study.
